PAVMZ News and Press, PAVmed Inc. Series Z Warrant From 11/02/22

Company conference call and webcast at 4:30 PM EDT Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced t...

PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a diversified commercial-stage medical device company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog, M.D., the Company&#x...

PAVmed press release ( NASDAQ: PAVM ): Q2 Non-GAAP EPS of -$0.17 beats by $0.03 . PAVmed had cash and cash equivalents of $65.2 million as of June 30, 2022, compared with $77.3 million as of December 31, 2021. Shares +3.03% . For further details see: ...

Lucid’s EsoGuard test volume grows 60% and LucidDx Labs fully operational Veris Health Cancer Care Platform to commercially launch this year Conference call to be held today at 4:30 PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Com...

Patients in Orange County, Dallas-Fort Worth, Palm Beach County, and Columbus, Ohio now have access to a brief, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer Lucid Diagnostics Inc. (Nasdaq: LUCD) (...

Updates best practice advice to support non-endoscopic esophageal precancer screening and significantly expands target population to include, for the first time, at-risk patients without chronic heartburn symptoms Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lu...

PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that its Chairman & Chief Executive Officer Lishan Aklog, M....

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chair...

PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc. ( Nasdaq: LUCD ) (“Lucid”), a commercial-stage cancer prevention medical...

Company conference call and webcast at 4:30 PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the Company will host a business update conference call on Thursday, May 12, 2022, ...